Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifungal agents in children.

William J Steinbach1

  • 1Department of Pediatrics, Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, NC 27710, USA. stein002@mc.duke.edu

Pediatric Clinics of North America
|June 1, 2005
PubMed
Summary

Systemic antifungal therapies are crucial for managing fungal infections in transplant recipients and children undergoing chemotherapy. This review covers currently approved drugs and emerging treatments for invasive fungal diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multifunctional Roles of Autophagy in Fungi.

Journal of fungi (Basel, Switzerland)·2026
Same author

Author Correction: Harnessing calcineurin-FK506-FKBP12 crystal structures from invasive fungal pathogens to develop antifungal agents.

Nature communications·2025
Same author

New Approaches and a Call to Action.

The Journal of pediatrics·2025
Same author

Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network.

Journal of the Pediatric Infectious Diseases Society·2024
Same author

Structure-guided design and synthesis of C22- and C32-modified FK520 analogs with enhanced activity against human pathogenic fungi.

bioRxiv : the preprint server for biology·2024

Area of Science:

  • Medical Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Fungal infections are a growing concern in immunocompromised patients, including organ transplant recipients and pediatric cancer patients.
  • Effective systemic antifungal therapy is essential for improving outcomes in these vulnerable populations.

Purpose of the Study:

  • To provide a comprehensive overview of current systemic antifungal treatments.
  • To discuss newly approved and anticipated antifungal agents.

Main Methods:

  • Literature review of systemic antifungal drugs.
  • Discussion of licensed and emerging antifungal medications.

Main Results:

  • Currently licensed drugs include amphotericin B, 5-fluorocytosine, azoles (fluconazole, itraconazole, voriconazole), and caspofungin.
  • Newer agents like second-generation azoles (posaconazole, ravuconazole) and echinocandins (micafungin, anidulafungin) are expected soon.

Conclusions:

  • A range of systemic antifungal agents are available and in development for managing invasive fungal infections.
  • Understanding these therapies is vital for clinicians treating high-risk patient populations.

Related Experiment Videos